United Therapeutics Stock Probability of Future Stock Price Finishing Over 369.09

UTHR Stock  USD 367.36  3.03  0.83%   
United Therapeutics' future price is the expected price of United Therapeutics instrument. It is based on its current growth rate as well as the projected cash flow expected by the investors. This tool provides a mechanism to make assumptions about the upside potential and downside risk of United Therapeutics performance during a given time horizon utilizing its historical volatility. Check out United Therapeutics Backtesting, United Therapeutics Valuation, United Therapeutics Correlation, United Therapeutics Hype Analysis, United Therapeutics Volatility, United Therapeutics History as well as United Therapeutics Performance.
To learn how to invest in United Stock, please use our How to Invest in United Therapeutics guide.
  
At this time, United Therapeutics' Price Earnings Ratio is relatively stable compared to the past year. As of 11/22/2024, Price Earnings To Growth Ratio is likely to grow to 0.35, while Price To Sales Ratio is likely to drop 4.20. Please specify United Therapeutics' target price for which you would like United Therapeutics odds to be computed.

United Therapeutics Target Price Odds to finish over 369.09

The tendency of United Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
Current PriceHorizonTarget PriceOdds to move over $ 369.09  or more in 90 days
 367.36 90 days 369.09 
about 30.99
Based on a normal probability distribution, the odds of United Therapeutics to move over $ 369.09  or more in 90 days from now is about 30.99 (This United Therapeutics probability density function shows the probability of United Stock to fall within a particular range of prices over 90 days) . Probability of United Therapeutics price to stay between its current price of $ 367.36  and $ 369.09  at the end of the 90-day period is under 4.
Given the investment horizon of 90 days the stock has the beta coefficient of 1.05 . This usually implies United Therapeutics market returns are sensible to returns on the market. As the market goes up or down, United Therapeutics is expected to follow. Additionally United Therapeutics has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the Dow Jones Industrial.
   United Therapeutics Price Density   
       Price  

Predictive Modules for United Therapeutics

There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as United Therapeutics. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.
Hype
Prediction
LowEstimatedHigh
365.63367.36369.09
Details
Intrinsic
Valuation
LowRealHigh
309.88311.61404.10
Details
Naive
Forecast
LowNextHigh
334.00335.73337.45
Details
16 Analysts
Consensus
LowTargetHigh
258.99284.60315.91
Details
Please note, it is not enough to conduct a financial or market analysis of a single entity such as United Therapeutics. Your research has to be compared to or analyzed against United Therapeutics' peers to derive any actionable benefits. When done correctly, United Therapeutics' competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy toward taking a position in United Therapeutics.

United Therapeutics Risk Indicators

For the most part, the last 10-20 years have been a very volatile time for the stock market. United Therapeutics is not an exception. The market had few large corrections towards the United Therapeutics' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold United Therapeutics, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of United Therapeutics within the framework of very fundamental risk indicators.
α
Alpha over Dow Jones
-0.03
β
Beta against Dow Jones1.05
σ
Overall volatility
16.33
Ir
Information ratio -0.02

United Therapeutics Alerts and Suggestions

In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of United Therapeutics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for United Therapeutics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.
United Therapeutics is unlikely to experience financial distress in the next 2 years
Over 98.0% of the company outstanding shares are owned by institutional investors
Latest headline from news.google.com: United Therapeutics Co. Shares Sold by Swiss National Bank - MarketBeat

United Therapeutics Price Density Drivers

Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of United Stock often depends not only on the future outlook of the current and potential United Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. United Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
Common Stock Shares Outstanding49.7 M
Cash And Short Term InvestmentsB

United Therapeutics Technical Analysis

United Therapeutics' future price can be derived by breaking down and analyzing its technical indicators over time. United Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of United Therapeutics. In general, you should focus on analyzing United Stock price patterns and their correlations with different microeconomic environments and drivers.

United Therapeutics Predictive Forecast Models

United Therapeutics' time-series forecasting models is one of many United Therapeutics' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary United Therapeutics' historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.

Things to note about United Therapeutics

Checking the ongoing alerts about United Therapeutics for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for United Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
United Therapeutics is unlikely to experience financial distress in the next 2 years
Over 98.0% of the company outstanding shares are owned by institutional investors
Latest headline from news.google.com: United Therapeutics Co. Shares Sold by Swiss National Bank - MarketBeat

Additional Tools for United Stock Analysis

When running United Therapeutics' price analysis, check to measure United Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy United Therapeutics is operating at the current time. Most of United Therapeutics' value examination focuses on studying past and present price action to predict the probability of United Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move United Therapeutics' price. Additionally, you may evaluate how the addition of United Therapeutics to your portfolios can decrease your overall portfolio volatility.